VERICEL CORPORATION Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture
VERICEL CORPORATION (VCEL) reported Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture of $9.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation · last filed 2026-07-30
- VERICEL CORPORATION shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-06-30 was $9.08M, a 10.42% decline year-over-year.
- VERICEL CORPORATION shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2026-03-31 was $11.29M, a 1.83% decline year-over-year.
- VERICEL CORPORATION shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-09-30 was $8.70M, a 5.69% decline year-over-year.
- VERICEL CORPORATION shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-06-30 was $10.14M, a 6.51% increase year-over-year.
- VERICEL CORPORATION shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2025 was $38.77M, a 6.23% increase from fiscal 2024.
- VERICEL CORPORATION shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2024 was $36.49M, a 12.90% increase from fiscal 2023.
- VERICEL CORPORATION shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2023 was $32.33M.
| Period end | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 6 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 9 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.08M 10-Q · filed 2026-07-30 | $20.38M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $11.29M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $38.77M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $8.70M 10-Q · filed 2025-11-06 | $18.84M derived: sum of 2 quarters · filed 2026-07-30 | $30.34M derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-06-30 | $10.14M 10-Q · filed 2026-07-30 | $21.64M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $11.51M 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $36.49M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $9.22M 10-Q · filed 2025-11-06 | $18.74M derived: sum of 2 quarters · filed 2025-11-06 | $28.58M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $9.52M 10-Q · filed 2025-11-06 | $19.35M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $9.83M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $32.33M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |